Contact
Please use this form to send email to PR contact of this press release:
Capricor Therapeutics to Meet with FDA to Discuss CAP-1002 to Treat Duchenne Muscular Dystrophy
TO:
Please use this form to send email to PR contact of this press release:
Capricor Therapeutics to Meet with FDA to Discuss CAP-1002 to Treat Duchenne Muscular Dystrophy
TO: